Julian Molina, MD, PhD, Mayo Clinic, Rochester, MN, discusses how the BASECAMP-1 trial (NCT04981119) is a leading example of precision medicine. The study aims to evaluate subjects with solid tumors with a high risk of relapse for incurable disease and who might benefit from future CAR T-cell therapy. In the future, CAR T-cells could be tailored based on the presence of human leukocyte antigen (HLA) loss. The BASECAMP-1 study focuses on HLA-A*02 loss, which is the most prevalent loss in the United States, but at some point, the loss of other HLA markers can be targeted as well. This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.